HD is an inherited condition that leads to destruction of nerve cells or neurons. The damage to nerve cells usually causes change in personality, mood swings, irritability and altered behavior. The global HD therapeutics market was witnessing a high unmet demand for disease modifying drug, in the presence of only one approved therapy, Xenazine, and the off-label use of various different therapeutics. The introduction of AUSTEDO in the market will have a significant impact on the market growth, thereby changing the market dynamics.
Technavio’s analysts forecast the global huntington’s disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021.
Covered in this report The report covers the present scenario and the growth prospects of the global huntington’s disease therapeutics market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off label drugs.
The market is divided into the following segments based on geography: • Americas • APAC • EMEA
Technavio’s report, Global Huntington’s Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors • F. Hoffmann-La Roche • H. Lundbeck • Prana Biotechnology • Teva Pharmaceutical Industries
Market driver • Early onset of disease symptoms, increases the demand for HD therapeutics • For a full, detailed list, view our report
Market challenge • Increase in alternative programs for management of mental disorders • For a full, detailed list, view our report
Market trend • Advances in biomedical sciences • For a full, detailed list, view our report
Key questions answered in this report • What will the market size be in 2021 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Our reports have been used by over 10K customers, including:
High levels of pipeline activity are being observed in Progressive Supranuclear Palsy treatment during 2019. Clinical development activities are being undertaken by more than 15 companies including AbbVie Inc, AC Immune, AlzProtect SAS, Aquinnah Pharmaceuticals, Asceneuron SA and others. A Significant contribution to the Progressive...
Pressure Ulcers - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers - Pipeline Review, H2 2019, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape. Pressure ulcers are an injury that breaks down the skin...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.